Welcome to LookChem.com Sign In|Join Free
  • or
IMIPRAMINE is a tricyclic antidepressant (TCA) medication that belongs to a class of drugs known as norepinephrine and dopamine reuptake inhibitors. It is primarily used to treat various types of depression and has additional applications in managing certain conditions related to motor clumsiness, enuresis in children, and Parkinson's disease. IMIPRAMINE works by increasing the levels of norepinephrine and dopamine in the brain, which helps to improve mood and alleviate depressive symptoms.

50-49-7

Post Buying Request

50-49-7 Suppliers

Recommended suppliers

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

50-49-7 Usage

Uses

Used in Pharmaceutical Industry:
IMIPRAMINE is used as an antidepressant for treating depression of various etiologies. It is particularly effective in managing symptoms such as low mood, loss of interest, and feelings of worthlessness or guilt.
Used in Pediatric Medicine:
IMIPRAMINE is used as a treatment for motor clumsiness and enuresis (bedwetting) in children. By increasing the levels of norepinephrine and dopamine in the brain, it can help improve motor coordination and bladder control.
Used in Neurology:
IMIPRAMINE is used in the management of Parkinson's disease, where it can help alleviate symptoms such as tremors, stiffness, and slow movement. The increased levels of norepinephrine and dopamine in the brain can improve motor function and overall quality of life for patients with Parkinson's disease.

Therapeutic Function

Antidepressant

Mechanism of action

Besides being used in the clinical treatment of depression, imipramine also has been used for the treatment of functional enuresis in children who are at least 6 years of age (25 mg daily administered 1 hour before bedtime, not to exceed 2.5 mg/kg daily).

Clinical Use

Imipramine is a 10,11-dihydrodibenzazepine tertiary amine TCA that is marketed as hydrochloride and pamoate salts, both of which are administered orally. Although the hydrochloride salt may be administered in divided daily doses, imipramine's long duration of action suggests that the entire oral daily dose may be administered at one time.On the other hand, imipramine pamoate usually is administered as a single daily oral dose.

Synthesis

Imipramine, 5-[3-(dimethylamino)propyl]-10,11-dihydro-5H-dibenz[b,f] azepine (7.1.1), is synthesized by the alkylation of 10,11-dihydro-5H-dibenz[b,f]azepine using 3-dimethylaminopropylchloride in the presence of sodium amide [1–3].

Check Digit Verification of cas no

The CAS Registry Mumber 50-49-7 includes 5 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 2 digits, 5 and 0 respectively; the second part has 2 digits, 4 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 50-49:
(4*5)+(3*0)+(2*4)+(1*9)=37
37 % 10 = 7
So 50-49-7 is a valid CAS Registry Number.
InChI:InChI=1/C19H24N2/c1-20(2)14-7-15-21-18-10-5-3-8-16(18)12-13-17-9-4-6-11-19(17)21/h3-6,8-11H,7,12-15H2,1-2H3

50-49-7Synthetic route

imipramine N-oxide
6829-98-7

imipramine N-oxide

impramine
50-49-7

impramine

Conditions
ConditionsYield
With sodium tetrahydroborate In water at 50 - 60℃; chemoselective reaction;96%
desipramine
50-47-5

desipramine

carbon dioxide
124-38-9

carbon dioxide

impramine
50-49-7

impramine

Conditions
ConditionsYield
With hydrogen In octane at 150℃; for 30h; Autoclave;89%
With hydrogen; tris(acetylacetonato)ruthenium(III); lithium chloride; [2-((diphenylphospino)methyl)-2-methyl-1,3-propanediyl]bis[diphenylphosphine] In tetrahydrofuran at 140℃; for 24h; Autoclave; Inert atmosphere;83 %Chromat.
With proazaphosphatrane; 9-bora-bicyclo[3.3.1]nonane In tetrahydrofuran at 90℃; under 750.075 Torr; for 1h; Inert atmosphere; Schlenk technique; chemoselective reaction;99 %Spectr.
N'-(4-carbomethoxy)desimipramine
876124-39-9

N'-(4-carbomethoxy)desimipramine

impramine
50-49-7

impramine

Conditions
ConditionsYield
With lithium aluminium tetrahydride In tetrahydrofuran for 0.5h; Heating;79%
formaldehyd
50-00-0

formaldehyd

didesmethylimipramine
2095-95-6

didesmethylimipramine

impramine
50-49-7

impramine

Conditions
ConditionsYield
With formic acid In water at 100℃; for 1h; Eschweiler-Clark Amine Methylation; Microwave irradiation;61%
1,2-bis(2-bromophenyl)ethane
59485-34-6

1,2-bis(2-bromophenyl)ethane

1-amino-3-(dimethylamino)propane
109-55-7

1-amino-3-(dimethylamino)propane

impramine
50-49-7

impramine

Conditions
ConditionsYield
With tris-(dibenzylideneacetone)dipalladium(0); sodium t-butanolate; XPhos In toluene at 110℃; Buchwald-Hartwig Coupling;60%
methanol
67-56-1

methanol

desipramine
50-47-5

desipramine

impramine
50-49-7

impramine

Conditions
ConditionsYield
With rhodium(III) chloride hydrate; potassium tert-butylate at 150℃; for 60h; Sealed tube; High pressure;49%
Clomipramine
303-49-1

Clomipramine

A

clomipramine N-oxide
14171-67-6

clomipramine N-oxide

B

impramine
50-49-7

impramine

C

3-hydroxyimipramine

3-hydroxyimipramine

D

3-hydroxyimipramine-N-oxide

3-hydroxyimipramine-N-oxide

Conditions
ConditionsYield
With oxygen In methanol; phosphate buffer at 25 - 28℃; pH=7.4; Product distribution; Further Variations:; Reagents; Photolysis; UV-irradiation;A 15%
B 15%
C 40%
D 20%
9,10-dihydrodibenzazepine
494-19-9

9,10-dihydrodibenzazepine

impramine
50-49-7

impramine

Conditions
ConditionsYield
With sodium amide; benzene und Erwaermen der Reaktionsloesung mit <3-Chlor-propyl>-dimethyl-amin;
9,10-dihydrodibenzazepine
494-19-9

9,10-dihydrodibenzazepine

3-(Dimethylamino)propyl chloride
109-54-6

3-(Dimethylamino)propyl chloride

impramine
50-49-7

impramine

Conditions
ConditionsYield
With sodium hydroxide; potassium carbonate DMSO 1.) room temp., 2 h, 2.) 110 deg C, 18 h; Yield given. Multistep reaction;
With potassium hydroxide; ammonium acetate In toluene at 20℃; Heating / reflux;
carbon dioxide
124-38-9

carbon dioxide

[3-(10,11-Dihydro-dibenzo[b,f]azepin-5-yl)-propyl]-methyl-trimethylsilanyl-amine

[3-(10,11-Dihydro-dibenzo[b,f]azepin-5-yl)-propyl]-methyl-trimethylsilanyl-amine

impramine
50-49-7

impramine

Conditions
ConditionsYield
With lithium aluminium tetrahydride 1.) THF, -45 deg C - 60 deg C, 2.) 60 deg C, 10 min; Yield given. Multistep reaction;
desipramine
50-47-5

desipramine

carbon dioxide
124-38-9

carbon dioxide

methyl chloroformate
79-22-1

methyl chloroformate

impramine
50-49-7

impramine

Conditions
ConditionsYield
Mechanism; multistep reaction; labelled with 11C;
desipramine hydrochloride
58-28-6

desipramine hydrochloride

impramine
50-49-7

impramine

Conditions
ConditionsYield
Multi-step reaction with 2 steps
1: (NH4)2SO4 / 110 °C
2: 2.) LiAlH4 / 1.) THF, -45 deg C - 60 deg C, 2.) 60 deg C, 10 min
View Scheme
desipramine
50-47-5

desipramine

impramine
50-49-7

impramine

Conditions
ConditionsYield
Multi-step reaction with 2 steps
2: 79 percent / LiAlH4 / tetrahydrofuran / 0.5 h / Heating
View Scheme
formic acid
64-18-6

formic acid

desipramine
50-47-5

desipramine

impramine
50-49-7

impramine

Conditions
ConditionsYield
With platinum(0)-1,3-divinyl-1,1,3,3-tetramethyldisiloxane complex; 1,3-bis-(diphenylphosphino)propane; phenylsilane In dibutyl ether at 60℃; for 18h; Schlenk technique; Inert atmosphere;92 %Chromat.
Imipramine hydrochloride
113-52-0

Imipramine hydrochloride

impramine
50-49-7

impramine

Conditions
ConditionsYield
With sodium hydroxide In water
Imipramine N-glucuronide
165602-94-8

Imipramine N-glucuronide

impramine
50-49-7

impramine

Conditions
ConditionsYield
With hydrogenchloride In water at 90℃;
impramine
50-49-7

impramine

methyl iodide
74-88-4

methyl iodide

Trimethyl-imipramine Iodide
16870-81-8

Trimethyl-imipramine Iodide

Conditions
ConditionsYield
In diethyl ether at 20℃; for 20h;98%
impramine
50-49-7

impramine

Pamoic acid
130-85-8

Pamoic acid

imipramine pamoate

imipramine pamoate

Conditions
ConditionsYield
In ethyl acetate at 20 - 50℃; Solvent; Temperature;96%
impramine
50-49-7

impramine

(6-bromohexyl)dimethyl-[3-(1,3-dioxo-1,3-dihydroisoindol-2-yl)propyl]ammonium bromide

(6-bromohexyl)dimethyl-[3-(1,3-dioxo-1,3-dihydroisoindol-2-yl)propyl]ammonium bromide

C38H52N4O2(2+)*2Br(1-)

C38H52N4O2(2+)*2Br(1-)

Conditions
ConditionsYield
In acetonitrile Heating;90%
1 ,6-dibromohexane
629-03-8

1 ,6-dibromohexane

impramine
50-49-7

impramine

(6-bromo-hexyl)-[3-(10,11-dihydro-dibenzo[b,f]azepin-5-yl)-propyl]-dimethyl-ammonium; bromide

(6-bromo-hexyl)-[3-(10,11-dihydro-dibenzo[b,f]azepin-5-yl)-propyl]-dimethyl-ammonium; bromide

Conditions
ConditionsYield
at 20℃;86%
impramine
50-49-7

impramine

C19H16(2)H8N2

C19H16(2)H8N2

Conditions
ConditionsYield
With deuterium In tetrahydrofuran for 36h; Glovebox; Inert atmosphere; regioselective reaction;84%
impramine
50-49-7

impramine

C19H16(2)H8N2

C19H16(2)H8N2

Conditions
ConditionsYield
With (1,5-cyclooctadiene)(methoxy)iridium(I) dimer; deuterium In tetrahydrofuran at 55℃; under 750.075 Torr; for 22h; Inert atmosphere;80%
impramine
50-49-7

impramine

methyl iodide
74-88-4

methyl iodide

imipramine methiodide
129344-89-4

imipramine methiodide

Conditions
ConditionsYield
In butanone for 1h; Ambient temperature;77%
Koshlands reagent I
772-33-8

Koshlands reagent I

impramine
50-49-7

impramine

2-((5-(3-(dimethylamino)propyl)-10,11-dihydro-5H-dibenzo[b,f]azepin-2-yl)methyl)-4-nitrophenol

2-((5-(3-(dimethylamino)propyl)-10,11-dihydro-5H-dibenzo[b,f]azepin-2-yl)methyl)-4-nitrophenol

Conditions
ConditionsYield
With dipotassium hydrogenphosphate In dichloromethane at 20℃; for 48h;73%
impramine
50-49-7

impramine

C24H30N2O5S

C24H30N2O5S

C43H54N4O5S

C43H54N4O5S

Conditions
ConditionsYield
With (4s,6s)-2,4,5,6-tetra(9H-carbazol-9-yl)isophthalonitrile; sodium acetate In N,N-dimethyl-formamide at 20℃; for 16h; Irradiation; Inert atmosphere; diastereoselective reaction;64%
impramine
50-49-7

impramine

1-bromo-2,3,4-tri-O-acetyl-α-D-glucuronic acid methyl ester
21085-72-3

1-bromo-2,3,4-tri-O-acetyl-α-D-glucuronic acid methyl ester

((2R,3R,4S,5S,6S)-6-Carboxy-3,4,5-trihydroxy-tetrahydro-pyran-2-yl)-[3-(10,11-dihydro-dibenzo[b,f]azepin-5-yl)-propyl]-dimethyl-ammonium; chloride
86492-48-0

((2R,3R,4S,5S,6S)-6-Carboxy-3,4,5-trihydroxy-tetrahydro-pyran-2-yl)-[3-(10,11-dihydro-dibenzo[b,f]azepin-5-yl)-propyl]-dimethyl-ammonium; chloride

Conditions
ConditionsYield
With XAD-2 ion-exchange resin; sodium hydrogencarbonate In water; benzene for 72h; Ambient temperature;55%
sodium cyanide
773837-37-9

sodium cyanide

impramine
50-49-7

impramine

A

9,10-dihydrodibenzazepine
494-19-9

9,10-dihydrodibenzazepine

B

2-((3-(10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)propyl)-(methyl)amino)acetonitrile

2-((3-(10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)propyl)-(methyl)amino)acetonitrile

C

2-(10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)-4-(dimethylamino)butanenitrile

2-(10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)-4-(dimethylamino)butanenitrile

Conditions
ConditionsYield
With [4,4’-bis(1,1-dimethylethyl)-2,2’-bipyridine-N1,N1‘]bis [3,5-difluoro-2-[5-(trifluoromethyl)-2-pyridinyl-N]phenyl-C]iridium(III) hexafluorophosphate; acetic acid In acetonitrile at 20℃; for 24h; Irradiation; Sealed tube;A 50%
B 22%
C 23%
potassium cyanide

potassium cyanide

impramine
50-49-7

impramine

A

9,10-dihydrodibenzazepine
494-19-9

9,10-dihydrodibenzazepine

B

2-((3-(10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)propyl)-(methyl)amino)acetonitrile

2-((3-(10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)propyl)-(methyl)amino)acetonitrile

C

2-(10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)-4-(dimethylamino)butanenitrile

2-(10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)-4-(dimethylamino)butanenitrile

Conditions
ConditionsYield
With 2-Picolinic acid; iron(III) chloride; tert-Butyl peroxybenzoate; 18-crown-6 ether In acetonitrile at 50℃; for 48h;A 6%
B 35%
C 15%
1 ,6-dibromohexane
629-03-8

1 ,6-dibromohexane

impramine
50-49-7

impramine

C44H60N4(2+)*2Br(1-)

C44H60N4(2+)*2Br(1-)

Conditions
ConditionsYield
In acetonitrile Heating;24%
impramine
50-49-7

impramine

A

10-Hydroxyimipramine
796-28-1

10-Hydroxyimipramine

B

2-hydroxyimipramine
303-70-8

2-hydroxyimipramine

C

4-hydroxyimipramine
94436-87-0

4-hydroxyimipramine

Conditions
ConditionsYield
Stage #1: impramine With ethylenediaminetetraacetic acid trisodium salt; oxygen; manganese (II) acetate tetrahydrate; ascorbic acid In water pH=4; Udenfriend reaction;
Stage #2: With ferrous(II) sulfate heptahydrate; ethylenediaminetetraacetic acid trisodium salt; oxygen In water at 45℃; for 2h; Udenfriend reaction;
A 2.56%
B 1.46%
C 3.47%
impramine
50-49-7

impramine

[14C]methanol
3046-50-2

[14C]methanol

C18(14)CH22N2O

C18(14)CH22N2O

Conditions
ConditionsYield
With oxygen; palladium on activated charcoal for 24h; Ambient temperature;
impramine
50-49-7

impramine

desipramine
50-47-5

desipramine

Conditions
ConditionsYield
With D-glucose; corn steep liquor; S. aureus; peptone; yeast extract In water at 37℃; Product distribution; other reagents;
With oxygen; palladium on activated charcoal In methanol for 24h; Ambient temperature;
With pooled human liver microsomes; Tris buffer; NADPH; magnesium chloride at 37℃; pH=7.4; Enzyme kinetics;
With human hepatic CYP1A2; human hepatic CYP2C9; human hepatic CYP3A4 Enzymatic reaction;
Multi-step reaction with 2 steps
1: N,N,N',N'-tetramethyl-1,8-diaminonaphthalene / 1,2-dichloro-ethane / 1 h / Reflux
2: 2 h / Reflux
View Scheme
impramine
50-49-7

impramine

2,8-dibromoimipramine
144434-72-0

2,8-dibromoimipramine

Conditions
ConditionsYield
With N-Bromosuccinimide; silica gel In dichloromethane at 18℃;

50-49-7Relevant academic research and scientific papers

Simple RuCl3-catalyzed N-Methylation of Amines and Transfer Hydrogenation of Nitroarenes using Methanol

Sarki, Naina,Goyal, Vishakha,Tyagi, Nitin Kumar,Puttaswamy,Narani, Anand,Ray, Anjan,Natte, Kishore

, p. 1722 - 1729 (2021/04/19)

Methanol is a potential hydrogen source and C1 synthon, which finds interesting applications in both chemical synthesis and energy technologies. The effective utilization of this simple alcohol in organic synthesis is of central importance and attracts scientific interest. Herein, we report a clean and cost-competitive method with the use of methanol as both C1 synthon and H2 source for selective N-methylation of amines by employing relatively cheap RuCl3.xH2O as a ligand-free catalyst. This readily available catalyst tolerates various amines comprising electron-deficient and electron-donating groups and allows them to transform into corresponding N-methylated products in moderate to excellent yields. In addition, few marketed pharmaceutical agents (e. g., venlafaxine and imipramine) were also successfully synthesized via late-stage functionalization from readily available feedstock chemicals, highlighting synthetic value of this advanced N-methylation reaction. Using this platform, we also attempted tandem reactions with selected nitroarenes to convert them into corresponding N-methylated amines using MeOH under H2-free conditions including transfer hydrogenation of nitroarenes-to-anilines and prepared drug molecules (e. g., benzocaine and butamben) as well as key pharmaceutical intermediates. We further enable one-shot selective and green syntheses of 1-methylbenzimidazole using ortho-phenylenediamine (OPDA) and methanol as coupling partners.

A fluorine-containing methyl compounds and its preparation method (by machine translation)

-

Paragraph 0179; 0180; 0185; 0186; 0187; 0188; 0338-0341, (2019/05/11)

The invention discloses a fluorine-containing methyl compounds and its preparation method. The invention provides a fluorine-containing shown as formula C methyl compounds, wherein R is aryl group containing, or, containing a hetero aryl group, and the aryl group or the heteroaryl on the aromatic carbon atom and CFm Hn Connected, m is 1 or 2, m + n=3. The compounds according to the prior art is difficult to make, the preparation method of the raw material and the catalyst are the ordinary industrial raw materials, cheap and easy to obtain, high reaction efficiency, high yield, after treatment is simple, low toxicity, environmental protection, functional group compatibility is good, broad-spectrum is strong, the production cost is low, it has very good market application prospect. (by machine translation)

A Focused Library of Psychotropic Analogues with Neuroprotective and Neuroregenerative Potential

Uliassi, Elisa,Pena-Altamira, Luis Emiliano,Morales, Aixa V.,Massenzio, Francesca,Petralla, Sabrina,Rossi, Michele,Roberti, Marinella,Martinez Gonzalez, Loreto,Martinez, Ana,Monti, Barbara,Bolognesi, Maria Laura

, p. 279 - 294 (2018/10/20)

Overcoming the lack of effective treatments and the continuous clinical trial failures in neurodegenerative drug discovery might require a shift from the prevailing paradigm targeting pathogenesis to the one targeting simultaneously neuroprotection and neuroregeneration. In the studies reported herein, we sought to identify small molecules that might exert neuroprotective and neuroregenerative potential as tools against neurodegenerative diseases. In doing so, we started from the reported neuroprotective/neuroregenerative mechanisms of psychotropic drugs featuring a tricyclic alkylamine scaffold. Thus, we designed a focused-chemical library of 36 entries aimed at exploring the structural requirements for efficient neuroprotective/neuroregenerative cellular activity, without the manifestation of toxicity. To this aim, we developed a synthetic protocol, which overcame the limited applicability of previously reported procedures. Next, we evaluated the synthesized compounds through a phenotypic screening pipeline, based on primary neuronal systems. Phenothiazine 2Bc showed improved neuroregenerative and neuroprotective properties with respect to reference drug desipramine (2Aa). Importantly, we have also shown that 2Bc outperformed currently available drugs in cell models of Alzheimer's and Parkinson's diseases and attenuates microglial activation by reducing iNOS expression.

Identification and Structural Characterization of Three New Metabolites of Bupropion in Humans

Sager, Jennifer E.,Choiniere, John R.,Chang, Justine,Stephenson-Famy, Alyssa,Nelson, Wendel L.,Isoherranen, Nina

supporting information, p. 791 - 796 (2016/08/24)

Bupropion is a widely used antidepressant and the recommended CYP2B6 probe drug. However, current understanding of bupropion elimination pathways is limited. Bupropion has three active circulating metabolites, OH-bupropion, threohydrobupropion, and erythrohydrobupropion, but together with bupropion these metabolites and their conjugates in urine represent only 23% of the dose, and the majority of the elimination pathways of bupropion result in uncharacterized metabolites. The aim of this study was to determine the structures of the uncharacterized bupropion metabolites using human clinical samples and in vitro incubations. Three new metabolites, 4′-OH-bupropion, erythro-4′-OH-hydrobupropion, and threo-4′-OH-hydrobupropion, were detected in human liver microsome incubations and were isolated from human urine. The structures of the metabolites were confirmed via comparison of UV absorbance, NMR spectra, and mass spectral data to those of the synthesized standards. In total, these metabolites represented 24% of the drug related material excreted in urine.

METHOD OF PREPARATION OF IMIPRAMINE PAMOATE AND NOVEL CRYSTALLINE FORM OF IMIPRAMINE PAMOATE THEREOF

-

Paragraph 0034, (2015/09/22)

The present invention is in relation to preparation of Imipramine Pamoate by a simple two-step process. The process provides new form of Imipramine Pamoate. The present invention is cost effective, involves mild conditions to beget said compound.

Csp3-Csp3 homocoupling reaction of benzyl halides catalyzed by rhodium

Sato, Kazuyuki,Inoue, Yuichi,Mori, Tomohisa,Sakaue, Atsushi,Tarui, Atsushi,Omote, Masaaki,Kumadaki, Itsumaro,Ando, Akira

supporting information, p. 3756 - 3759 (2014/08/05)

A highly reactive alkylrhodium complex was formed from Me2Zn and RhCl(PPh3)3 and effectively catalyzed a Csp 3-Csp3 homocoupling reaction of benzyl halides. A Csp 3-Csp3 coupling reaction using Rh catalyst has not been reported up to now. The reaction proceeded under very mild conditions and gave the corresponding homocoupling products even if they had reactive substituents such as an uncovered formyl or hydroxymethyl group.

N-Methylation of amine and nitro compounds with CO2/H2 catalyzed by Pd/CuZrOx under mild reaction conditions

Cui, Xinjiang,Zhang, Yan,Deng, Youquan,Shi, Feng

supporting information, p. 13521 - 13524 (2015/01/09)

An active Pd/ZrCuOx catalyst was prepared for the reductive amination of CO2. The N-methylation of amines and nitro compounds with CO2/H2 can be realized with up to 97% yield under relatively mild reaction condi

Carbon Dioxide Reduction to Methylamines under Metal-Free Conditions

Blondiaux, Enguerrand,Pouessel, Jacky,Cantat, Thibault

, p. 12186 - 12190 (2016/02/23)

The first metal-free catalysts are reported for the methylation of amines with carbon dioxide. Proazaphosphatrane superbases prove to be highly active catalysts in the reductive functionalization of CO2, in the presence of hydroboranes. The new methodology enables the methylation of N-H bonds in a wide variety of amines, including secondary amines, with increased chemoselectivity. Organocatalysis: Proazaphosphatrane superbases prove to be highly active catalysts in the reductive functionalization of CO2, in the presence of hydroboranes. The new method makes possible the methylation of N-H bonds in a wide variety of amines, including secondary amines (see picture), with increased chemoselectivity.

General catalytic methylation of amines with formic acid under mild reaction conditions

Sorribes, Ivan,Junge, Kathrin,Beller, Matthias

supporting information, p. 7879 - 7883 (2014/07/07)

A general catalytic protocol for the methylation of amines has been developed applying, for the first time, formic acid as the C1 building block and silanes as reducing agents. A broad range of aromatic and aliphatic, both primary and secondary, amines has been converted to the corresponding tertiary amines including [N-13C]-labelled drugs in good to excellent yields under mild conditions. Methylation made easy: A general catalytic protocol for the methylation of amines has been developed applying, for the first time, formic acid as the C1 building block and silanes as reducing agents. A broad range of aromatic and aliphatic, both primary and secondary, amines has been converted to the corresponding tertiary amines, including [N-13C]-labelled drugs, in good to excellent yields at mild conditions (see scheme; dppp=(1,3-bis(diphenylphosphino)propane)).

Selective methylation of amines with carbon dioxide and H2

Li, Yuehui,Sorribes, Ivan,Yan, Tao,Junge, Kathrin,Beller, Matthias

supporting information, p. 12156 - 12160 (2013/12/04)

Put a label on it: Carbon dioxide with H2 is shown to be an efficient and selective methylation reagent for aromatic and aliphatic amines (see scheme; acac=acetylacetonate, triphos = 1,1,1- tris(diphenylphosphanylmethyl)ethane). A variety of functionalized amines including 13C-labelled drugs were obtained with good yields and functional-group tolerance. Copyright

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1 Customer Service

What can I do for you?
Get Best Price

Get Best Price for 50-49-7